News

". . . for too long, drug manufacturers have been allowed to game the system by submitting numerous or baseless, bogus petitions simply so the FDA will delay competing manufacturers’ approvals. . . . The Stop STALLING Act is sound, bipartisan legislation that promises to stop this problem for good."

". . . if the branded manufacturer denies the provision of samples, it can delay its competitor’s approval and prop up its own drug’s high costs. This should not be happening. . . . The CREATES Act will prevent this kind of gaming and make sure that generic and biosimilar manufacturers can gain samples to complete testing and win FDA approvals."

"The Preserve Access to Affordable Generics and Biosimilars Act would . . .  accelerate the lowering of prescription drug prices in America. . . . [and] prevent anticompetitive settlements that line drug company pockets while consumers pay the bill."

“The Prescription Pricing for the People Act of 2019 would shed light on how PBMs are affecting prescription costs and patient choice. This would support Congress as it crafts evidence-based solutions to address the anticompetitive role PBMs play as pharmaceutical costs continue to rise.”

"A review of some of the passages from pages 168-180 make the summary on page 7-8 crystal clear in recognizing the summary is about congressional lawmaking authority under separation-of-powers when constitutional tensions exist between the President’s official Article II actions and obstruction of justice statutes. . . . The absence of any statement asking Congress to serve in a prosecutorial capacity in an obstruction of justice case should not be surprising, because that is not Congress’s role — it is the role of the Department of Justice."